Respiratory

PRA has significant experience in the area of respiratory/allergy clinical research. Our expertise covers a range of indications across the areas of allergic rhinitis, asthma, COPD, endocrine, cystic fibrosis and pulmonary fibrosis. PRA has been involved in the market approvals of three major drugs in this area. Our development projects have covered most respiratory/allergy drug areas including:

Leukotriene modifier / Inhaled and nasal corticosteroids / Short- and long-acting beta2 agonists
Anticholinergic agents / Phosphodiesterase inhibitors / Mast-cell stabilizers / Anti-IgE antibodies

PRA has conducted 70 respiratory disease trials with nearly half of our experience in the two biggest areas of threat – asthma and COPD.

Experience and Expertise

In addition to the consulting services that we have provided for more than 30 projects, we have managed clinical development programs in these key areas.

 

Key Areas of Respiratory Expertise

Respiratory/Allergy Number of Clinical Studies Number of Clinical Sites Number of Clinical Patients
COPD 20 1,759 4,849
Mild/Moderate Asthma 18 254 2,533
Moderate/Severe Asthma 9 164 704
Seasonal Allergic Rhinitis 9 246 2,499
Cystic Fibrosis 4 4 198
Total 60 2,400+ 10,700+

PRA’s respiratory therapeutic experts include:

  • Board-certified pulmonologists and recognized experts in pulmonary function testing on staff
  • Committee members and fellowships with major professional societies including, The American Thoracic Society, European Respiratory Society, American College of Chest Physicians and American Association for Respiratory Care
  • Established relationships with investigators and leaders in respiratory clinical research
  • Expertise in maximizing standardization of key respiratory assessments

Allergy Research

PRA is a leader in allergy drug research. We have had various levels of involvement with the majority of approved allergy medications currently on the US market. More than 60 of our monitors and clinical team managers are experienced with allergic rhinitis studies.